Effects of finerenone on readmissions for heart failure: a prespecified secondary analysis of the FINEARTS-HF trial

19 May 2025 (13:45 - 13:55)

Organised by:

Video

Sign in for access options

Slides

About the speaker

Doctor Ankeet Bhatt

Kaiser Permanente, San Francisco Medical Centre and Medical Offices, San Francisco (United States of America)

6 More presentations in this session

Presentation thumbnail

Discussant panel

Presentation thumbnail

Trade-off of risk and benefit of finerenone across the spectrum of kidney function in patients with heart failure with mildly reduced and preserved ejection fraction in the FINEARTS-HF trial

Doctor S. Chatur (Boston, US)

Presentation thumbnail

Intravenous ferric carboxymaltose in heart failure with iron deficiency

Doctor M. Karakas (Hamburg, DE)

Presentation thumbnail

Efficacy of intravenous iron for the treatment of heart failure varies by method of meta-analysis: a Bayesian and frequentist reappraisal of the evidence

Doctor A. Henderson (Glasgow, GB)

Presentation thumbnail

The effect of omecamtiv mecarbil on outcomes analysed using the win ratio: an exploratory analysis of GALACTIC-HF

Doctor K. Docherty (Glasgow, GB)

Access the full session

Session thumbnail

Clinical trials updates in medical therapy

The Event

Event poster

Heart Failure 2025

19 May 2025 13:45 CET

You may be interested in

Congress Presentation

Finerenone in patients with severe heart failure: the FINEARTS-HF Trial

Congress Presentation

Finerenone

Congress Presentation

Non-steroidal mineralocorticoid receptor antagonists (nsMRAs) in heart failure with mid-range and preserved ejection fraction: establishing a new standard in heart failure care

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources